Use access key #2 to skip to page content.
$3.56 -0.01 (-0.28%)
5/9/2008 4:00 PM

BioSante Pharmaceuticals, Inc. (BPAX)

CAPS Rating:
**

A biopharmaceutical company that licenses and develops hormone therapy products to treat men and women.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

BPAX doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks Add a widget featuring this stock to your blog!

Total Players

67 Outperforms
13 Underperforms
 

All-Stars

9 Outperforms
7 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Players bullish on BPAX are also bullish on:

Players bearish on BPAX are also bearish on:

Ticker Tags

Rule Breakers Universe (161), Micro Cap (4824), Nanotechnology (28), Biotechnology (291)
Suggest a tag

BioSante Pharmaceuticals, Inc. At A Glance

Current Price: $3.56
Last Trade Time: 5/9/2008 4:00 PM
Open: $3.59
Previous Close: $3.57
Daily Range: $3.50 - $3.59
52-Week Range: $2.05 - $8.00
Volume: 22,575
Market Cap: $95.67M
P/E Ratio: 11.26
Compare Our Special Broker Offers!

Stock Trends

BPAX VS S&P 500 (SPY)

BPAX 12 month chart vs. S&P

News & Discussion Boards

Sorry no news articles available for BPAX.

Top Bull Pitch

Recs

1

BioSante Pharmaceuticals, Inc. (BPAX)

Avatar tibber61 (71.72) Submitted: 3/28/07 9:28 PM

Unlike most bio firms, tech research companies focused on delivery systems seem to yield larger "hits" than "misses" by applying their discoveries over broader markets; most traditional biotechs seem to have too narrow a focus, leading to significant company impact when trials fail.

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

2

BioSante Pharmaceuticals, Inc. (BPAX)

Avatar tweakie (< 20) Submitted: 2/05/08 2:46 AM

Why the heck did the CEO write to Adam Feuerstein??? Poor leadership.

Replies: 1 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 15 :   1 2 3 Next »

Show Pitch Replies

Recs

0

 (BPAX)

Avatar zzlangerhans (< 20) Submitted: 4/15/08 2:52 AM : Underperform Start Price: $4.02 BPAX Score: 15.50

I'm going to come down on the negative side on Biosante while the cap is still above 100M. Biosante basically has Elestrin and LibiGel. Elestrin was approved in 12/06 and doesn't seem to have generated any significant revenues whatsoever, a fact the company seems to be obfuscating in quarterly statements. LibiGel has been making progress, but even if all phase III trials are successful the CEO doesn't predict an NDA before 2010. That's a lot of time for Biosante stock to slide back down into the 60M cap it was occupying before the recent odd price bump. Toss in a liberal helping of snake oil salesmanship and historical shortcomings, and my skepticism is solid.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BPAX)

Avatar EclecticRecluse (71.43) Submitted: 4/01/08 8:34 AM : Underperform Start Price: $4.64 BPAX Score: 27.18

Pullback Expected on Relatively Weak Stock

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (BPAX)

Avatar mojotronic (53.22) Submitted: 3/28/08 4:54 PM : Outperform Start Price: $4.72 BPAX Score: -30.37

Check the bullish analyst ratings and the three month chart.
This stock is just catching fire.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (BPAX)

Avatar BrianRuth (99.46) Submitted: 3/06/08 2:18 AM : Underperform Start Price: $5.75 BPAX Score: 32.33

I hope their sexygel works. I really do. But someone needs to be on the red thumb side of this stock and call (Penn & Teller) bull$#!*.

Report this Post Replies: 0 | Reply | Permalink

Recs

2

 (BPAX)

Avatar tweakie (< 20) Submitted: 2/05/08 2:46 AM : Underperform Start Price: $3.83 BPAX Score: 9.23

Why the heck did the CEO write to Adam Feuerstein??? Poor leadership.

Report this Post Replies: 1 | Reply | Permalink

Results 1 - 5 of 15 :   1 2 3 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackOppenheimer < 20 08/23/07 Outperform NS $5.65-36.99%-5.73%-31.26

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners